How to Earn an 86% Gain in Just 1 Hour

What makes this particularly interesting is that... [Energy and Capital Header] Practical Investment Analysis for the New Energy Economy How to Earn an 86% Gain in Just 1 Hour Jeff Siegel | Mar 11, 2024 Check out this chart … [mnmd11] At one point, this stock was up 86.8% in just over an hour. This is what happened to MindMed (NASDAQ: MNMD) on Wednesday after it was announced that the company had received breakthrough designation status from the FDA for its treatment for generalized anxiety disorder. If you’re unfamiliar, the FDA grants breakthrough status for drugs that treat life-threatening conditions, and clinical evidence shows that those drugs demonstrate substantial improvement over currently available treatments. The Single Most Important Geological Discovery of Our Generation A tiny mining firm is at the forefront of mining the world's largest lithium deposit... And it’s NOT overseas in some politically unstable nation... Every single ounce of this record-breaking deposit is right here in America. With an estimated value of $1.5 trillion, it's about to launch this $5 stock into the stratosphere... [See the full details here.]( What makes this particularly interesting, however, is that MindMed’s new medication is an EN-23 medication. I literally just told you about EN-23 on Friday, writing … EN-23 is a valuable class of molecules that drastically improves brain function. It’s actually one of the biggest breakthroughs medical science has seen in 50 years, because not only can it treat mental health conditions such as depression, anxiety, PTSD and addiction, it also has the ability to help you lose weight, treat chronic pain and even extend your lifespan by up to 20 years. While EN-23 isn’t necessarily new, the FDA is expected to approve the nation’s first EN-23 medication in August developed by company called Lykos Therapeutics. This company has developed a new and incredibly effective treatment for PTSD. That company isn’t public, but there are a number of other EN-23 companies that are. Three in particular are actively working with the FDA to get their own EN-23 therapies through clinical trials and ultimately out into the market. I wrote about those companies in a recent investment note, which you can [access here.]( Truth is, I’ve been following the EN-23 space for nearly ten years now.  Amazon Just Got B****-Slapped Amazon has been fined $1.28 billion for dominating Italy’s e-commerce market. According to Italian antitrust regulators, Amazon used its logistics service to block competitors from gaining visibility and making sales. But Amazon is a $1.3 trillion company. To Amazon, paying this fine is like spending quarters at a gumball machine. And the company is still poised to make over $540 billion by the end of the year. But I’m not touching Amazon stock. And you shouldn’t either. Owning its stock would mean sharing in all the fines and losses its shareholders are racking up. Instead, you could use my blueprint to "backdoor" Amazon without owning a single share — earning regular payouts that I call “Prime Profits.” [It only takes two minutes to get set up for collecting these payouts, and the next one is coming on March 14.]( I’ve been watching it grow from little more than a big idea to a market that’s producing what could easily be the most profitable drug in human history. It could quite literally replace … - The alcohol treatment market — currently valued at $35 billion. - The PTSD treatment market — currently valued at around $90 billion - The market for diabetes treatments — estimated to be worth about $16.4 billion - The smoking cessation market — currently valued at $39 billion. - The anti-aging drug market — currently valued at $54 billion. - The neurodegenerative disease treatment market — currently valued at $40 billion - The depression treatment market — currently valued at $150 billion - The sexual enhancement drug market —currently valued at $10 billion - The market for anorexia treatments — valued at $2.1 billion - The market for treating chronic pain — valued at $635 billion Just those 10 markets alone, you’re looking at more than $1 trillion up for grabs. And the FDA is fast-tracking the approval of EN-23! Now at the moment, there are two EN-23 companies in particular that are next in line for breakthrough status designation from the FDA. And when that happens, expect to see the same result we saw last week with MindMed. Here it is again, just as a reminder … [mnmd11] Don’t sleep on this opportunity. The FDA is literally giving us all the intel we need to make a ton of cash from its move to fast-track new EN-23 medications that are on the cusp of FDA approval. And [these are the EN-23 companies you want to own now — before]([that happens](. To a new way of life and a new generation of wealth... [Jeff Siegel Signature] Jeff Siegel [[follow basic]Check us out on YouTube!]( [[follow basic]@JeffSiegel on Twitter]( Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor's [page](. [Fb]( [Li]( [Tw]( This email was sent to {EMAIL}. You can manage your subscription and get our privacy policy [here](. Energy and Capital, Copyright © 3 East Read Street, Baltimore, MD 21202. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info [here]( including our privacy policy and information on how to manage your subscription. If you are interested in our other publications, please call our customer service team at [1-877-303-4529](tel:/18773034529).